-
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. NPJ Precis Oncol. 2024 Feb 14; 8(1):34.
Walmsley CS, Jonsson P, Cheng ML, McBride S, Kaeser C, Vargas HA, Laudone V, Taylor BS, Kappagantula R, Baez P, Richards AL, Noronha AM, Perera D, Berger M, Solit DB, Iacobuzio-Donahue CA, Scher HI, Donoghue MTA, Abida W, Schram AM. PMID: 38355834; PMCID: PMC10866935.
View in:
PubMed Mentions:
-
Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer Immunol Res. 2024 Jan 26.
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. PMID: 38276989.
View in:
PubMed Mentions: Fields:
-
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma. J Thorac Oncol. 2023 Dec 27.
Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA. PMID: 38154515.
View in:
PubMed Mentions:
1 Fields:
-
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24; 389(8):710-721.
Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J, GO42144 Investigator and Study Group. PMID: 37611121.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCTClinical Trials
-
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 07 05; 29(13):2540-2550.
Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, Shapiro GI, Park H, Nishino M, Lindsay J, Felt KD, Sharma B, Cherniack AD, Rodig S, Gomez DR, Shaverdian N, Rakaee M, Bandlamudi C, Ladanyi M, Janne PA, Schoenfeld AJ, Sholl LM, Awad MM, Cheng ML. PMID: 37097610.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precis Oncol. 2023 Jun; 7:e2200633.
Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA. PMID: 37384867; PMCID: PMC10581614.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022 11; 6:e2200382.
Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, Jänne PA. PMID: 36455195.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers (Basel). 2022 Aug 23; 14(17).
Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. PMID: 36077617; PMCID: PMC9454848.
View in:
PubMed Mentions:
10
-
Lipid pneumonia associated with mineral oil use presenting as fluorine-18-fluorodeoxy-D-glucose-avid lung mass. JTCVS Tech. 2022 Oct; 15:192-194.
Cheng ML, Thomas V, Vaz N, Hammer MM, Nishino M, Vargas SO, Khalil HA. PMID: 36276695; PMCID: PMC9579874.
View in:
PubMed Mentions:
-
Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505.
French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. PMID: 35417004; PMCID: PMC9197941.
View in:
PubMed Mentions:
15 Fields:
Translation:
Humans
-
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. JTO Clin Res Rep. 2022 Jul; 3(7):100347.
Schneider JL, Muzikansky A, Lin JJ, Krueger EA, Lennes IT, Jacobson JO, Cheng M, Heist RS, Piotrowska Z, Gainor JF, Shaw AT, Dagogo-Jack I. PMID: 35815322; PMCID: PMC9257415.
View in:
PubMed Mentions:
4
-
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precis Oncol. 2021 11; 5:726-732.
Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, Jänne PA. PMID: 34994618.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021 07; 16(7):1176-1187.
Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. PMID: 33845210.
View in:
PubMed Mentions:
33 Fields:
Translation:
Humans
-
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 2021 05 31; 13(1):96.
Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, Srinivasan P, Huberman K, Meng F, Jing X, Patel J, Hasan M, Johnson I, Gedvilaite E, Houck-Loomis B, Socci ND, Selcuklu SD, Seshan VE, Zhang H, Chakravarty D, Zehir A, Benayed R, Arcila M, Ladanyi M, Funt SA, Feldman DR, Li BT, Razavi P, Rosenberg J, Bajorin D, Iyer G, Abida W, Scher HI, Rathkopf D, Viale A, Berger MF, Solit DB. PMID: 34059130; PMCID: PMC8165771.
View in:
PubMed Mentions:
14 Fields:
Translation:
Humans
-
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021 03; 9(3).
Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. PMID: 33771889; PMCID: PMC7996662.
View in:
PubMed Mentions:
51 Fields:
Translation:
Humans
-
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precis Oncol. 2021; 5.
Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP. PMID: 34250387; PMCID: PMC8232122.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA Cancer J Clin. 2021 03; 71(2):176-190.
Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. PMID: 33165928.
View in:
PubMed Mentions:
64 Fields:
Translation:
Humans
-
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precis Oncol. 2020; 4.
Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, Isharwal S, Iyer G, Funt S, Bagrodia A, Bajorin DF, Reuter VE, Eng J, Joseph G, Bourque C, Bromberg M, Ling L, Selcuklu SD, Arcila ME, Tsui DWY, Zehir A, Viale A, Berger MF, Bosl GJ, Sheinfeld J, Van Allen E, Taylor BS, Al-Ahmadie H, Solit DB, Feldman DR. PMID: 33163850; PMCID: PMC7608584.
View in:
PubMed Mentions:
7 Fields:
-
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO Precis Oncol. 2020; 4.
Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, Jänne PA, Oxnard GR. PMID: 33015530; PMCID: PMC7529535.
View in:
PubMed Mentions:
6 Fields:
-
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142.
Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. PMID: 32332016.
View in:
PubMed Mentions:
73 Fields:
Translation:
HumansCells
-
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Res. 2020 02; 30(1):71-75.
Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD. PMID: 31425479; PMCID: PMC7485135.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 2020 02; 140:35-41.
Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM. PMID: 31855703.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019 07; 571(7766):576-579.
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. PMID: 31292550; PMCID: PMC7048239.
View in:
PubMed Mentions:
175 Fields:
Translation:
HumansCells
-
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019 Apr 01; 5(4):471-478.
Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. PMID: 30589920; PMCID: PMC6459218.
View in:
PubMed Mentions:
248 Fields:
Translation:
HumansCells
-
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018 09 10; 34(3):427-438.e6.
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. PMID: 30205045; PMCID: PMC6327853.
View in:
PubMed Mentions:
424 Fields:
Translation:
HumansCells
-
Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC? Clin Cancer Res. 2019 02 01; 25(3):899-900.
Cheng ML, Oxnard GR. PMID: 30190372; PMCID: PMC6359945.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
Clinical tumour sequencing for precision oncology: time for a universal strategy. Nat Rev Cancer. 2018 09; 18(9):527-528.
Cheng ML, Berger MF, Hyman DM, Solit DB. PMID: 30030494; PMCID: PMC6618305.
View in:
PubMed Mentions:
15 Fields:
Translation:
Humans
-
Novel biomarkers in bladder cancer. Urol Oncol. 2018 03; 36(3):115-119.
Cheng ML, Iyer G. PMID: 29472156.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Ann Intern Med. 2018 02 06; 168(3):221-222.
Cheng ML, Solit DB. PMID: 29310131; PMCID: PMC6659420.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol. 2015 Apr; 39(2):143-9.
Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. PMID: 25662402; PMCID: PMC4470609.
View in:
PubMed Mentions:
32 Fields:
Translation:
Humans
-
Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol. 2014 Mar; 15(1):115-26.
Cheng ML, Fong L. PMID: 24402184; PMCID: PMC4523381.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 2014 Jan 07; 3:329.
Cheng ML, Fong L. PMID: 24432249; PMCID: PMC3882875.
View in:
PubMed Mentions:
39
-
Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Jan; 14(1):91-6.
Ryan CJ, Cheng ML. PMID: 23199349.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Coccidioidal endophthalmitis in immunocompetent person, California, USA. Emerg Infect Dis. 2012 Jun; 18(6):1015-6.
Cheng ML, Leibowitz M, Ha E. PMID: 22608196; PMCID: PMC3358163.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansAnimals